Ron Bentsur

Ron Bentsur (CEO) bought 12,500 shares at $20.00 on 2026-06-30; stock now $19.47, down 33.5% from 52-week high but up 99.7% in 30 days.

Ron Bentsur's purchase of 12,500 shares at $20.00 follows a pattern of prior insider buys at NVCT where 4 of 5 earlier trades showed positive 90-day returns. His most recent buy on 2025-11-05 returned +17.3% in 30 days and +48.2% in 90 days; the 2024-12-24 buy returned +38.1% in 30 days and +111.0% in 90 days, demonstrating successful timing on near-term rallies at this ticker. The current transaction occurs as the stock has surged 99.7% in the last 30 days, having recovered sharply from a 52-week low of $5.55. However, investors should note the company remains unprofitable with net income of -$6,050,000.00 over its most recent full fiscal year, and the stock remains 33.5% below its 52-week high of $29.28. The timing of this buy into a momentum-driven rally, combined with the company's ongoing losses, creates tension between price-action signals and fundamental deterioration.

NVCT Chairman & CEO Bentsur buys 5,000 shares at $5.72 as stock down -48.4% from 52-week high; cluster of 4 insider buys in 14 days.

Ron Bentsur, as Chairman & CEO, purchased 5,000 shares at $5.72 on 2025-11-05, adding to holdings of 3.53M shares. The transaction occurs as NVCT trades -48.4% below its 52-week high of $10.98 and down -7.2% over the prior 30 days, against a backdrop of full-year net income of $-7,462,000.00. Notably, this buy is part of a cluster pattern: 3 other insiders also bought within the past 14 days. Bentsur's prior trades at NVCT show mixed timing results—3 of 5 prior buys ultimately produced positive 90-day returns, with his most recent buy on 2024-12-24 returning +111.0% over 90 days. However, his broader cross-ticker open-market history shows weaker predictive power: 20 prior buys averaging -17.8% return over 90 days with only a 15.00% win rate. The convergence of multiple insider purchases during a significant drawdown warrants investor attention to whether insiders perceive the decline as an opportunity, although the company's unprofitable state and the insider's mixed historical timing record limit conviction signals.

NVCT CEO Ron Bentsur buys 4,500 shares at $4.65 on 2024-12-24; stock now $5.02, down 54.4% from 52-week high of $11.00.

Ron Bentsur, Chairman & CEO, purchased 4,500 shares at $4.65 on 2024-12-24, increasing holdings to 3,270,924 shares. At the current price of $5.02, the stock is -54.4% from its 52-week high and down 18.8% over the past 90 days. Bentsur's cross-ticker track record shows an average 90-day return of -28.2% across 19 prior open-market buys, with only a 5.56% win rate at the 90-day horizon. His NVCT-specific history also reveals a weak timing pattern: of 5 prior trades at this ticker, only 1 achieved a positive 90-day return, and a March 2024 buy suffered a -34.3% 30-day drawdown followed by -34.2% over 90 days. The company reported net income of $-4,153,000.00 for its most recent full fiscal year, indicating unprofitability. The purchase occurs amid ongoing price deterioration and a track record of poor execution at identifying rebounds.

NVCT CEO Ron Bentsur buys 20,000 shares at $4.92; stock down 54.2% from 52-week high, insider's prior buys underperformed.

Ron Bentsur, Chairman & CEO, purchased 20,000 shares of Nuvectis Pharma at $4.92 on 2024-11-15, increasing his holdings to 3.27M shares. The purchase occurs after a sharp decline: the stock is down 54.2% from its 52-week high of $11.00 and has fallen 33.7% over the prior 30 days. However, Bentsur's historical buy timing at NVCT has been poor—of his 5 prior purchases at this ticker, only 1 achieved positive 90-day returns, and his most recent buys in May 2024 showed mixed results (one +1.3% at 30 days but negative at 90 days; the other -0.9% at 30 days). His cross-ticker track record shows an average 90-day return of -28.2% across 18 prior buys, with a 90-day win rate of only 5.56%. The company remains unprofitable with net income of $-4.2M over its most recent full fiscal year, adding fundamental headwinds to the technical weakness surrounding this purchase.